Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Lessons From Lockdown: Viral Hepatitis Testing and Treatment in the COVID-19 Era—Audio Recap

Source: Lessons From Lockdown: Evolving Models of Care for Liver Diseases
In this engaging dialogue, 2 expert hepatologists discuss strategies for improving linkage to care of patients with viral hepatitis despite the challenges posed by the COVID-19 pandemic.
Jordan J. Feld, MD, MPH
Nancy Reau, MD
Released: March 14, 2022

In this episode, Jordan J. Feld, MD, MPH, and Nancy Reau, MD, share lessons learned in the testing and treatment of viral hepatitis in the COVID-19 era, including:

  • Global impact of the COVID-19 pandemic on viral hepatitis testing and linkage to care
  • Impact of COVID-19 pandemic on testing and treatment in the United States and Canada
  • Innovative strategies to improve linkage to care of patients with viral hepatitis during the COVID-19 pandemic

Information on this Educational Activity

Faculty

Jordan J. Feld, MD, MPH

Professor of Medicine
University of Toronto
Hepatologist
Toronto Centre for Liver Disease
Sandra Rotman Centre for Global Health
Toronto, Canada

Jordan J. Feld, MD, MPH, has disclosed that he has received consulting fees from AbbVie, Arbutus, Antios, Eiger, Enanta, Gilead Sciences, GlaxoSmithKline, and Janssen and funds for research support from AbbVie, Alexion, Deep Genomics, Gilead Sciences, Eiger, Enanta, Finch, Janssen, and Wako/Fujifilm.
Nancy Reau, MD

Professor of Medicine
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Richard B. Capps Chair of Hepatology
Rush University Medical Center
Chicago, Illinois

Nancy Reau, MD, has disclosed that she has received consulting fees from AbbVie, Arbutus, Antios, Gilead Sciences, Intercept and Salix and funds for research support from AbbVie, Eiger, and Gilead Sciences.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grants provided by:
AbbVie
Gilead Sciences, Inc.

Related Content

Dr Nancy Reau on exciting viral hepatitis data from EASL 2022, including HBV, HDV (hepatitis delta), and HCV, from Clinical Care Options (CCO)

Nancy Reau, MD Released: July 13, 2022

Clinical Care Options (CCO) expert analysis by Prof Tarik Asselah on new viral hepatitis data from EASL 2022, including HBV, HDV, and HCV

Tarik Asselah, MD, PhD Released: July 8, 2022

Expert selections of important viral hepatitis data from EASL 2022, including studies of patients with HBV, HDV (hepatitis delta virus), and HCV, from Clinical Care Options (CCO)

Tarik Asselah, MD, PhD Stefan Zeuzem, MD Released: July 6, 2022

Clinical Care Options (CCO) commentary from a patient who shares their experience of severe liver disease from HBV/HDV coinfection

person default Joaquín (Patient) Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: June 29, 2022 Expired: June 28, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings